StockUS listing USHBMHFPINKHealthcareQuality Compounder

HBM Holdings Limited(HBMHF) Stock Analysis | Healthcare

USD --+0.00%
Reward65Moderate
Risk56Medium-High
75%Data
Strong 63% profit margin · Revenue growing 328% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 1.30Bn
Reward Ratingⓘ65 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ56 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on HBMHF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is HBM Holdings Limited?

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally.

AI Brief Pro

The brief on HBM Holdings Limited

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is HBM Holdings Limited?

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.30B, and a P/E ratio of 17.3x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (65)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
P/E Ratio17.3333
Beta1.738
Insider Activity
12M windowNo data
No insider activity data available for this ticker.